BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25752763)

  • 21. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
    Kiaris H; Chatzistamou I; Schally AV; Halmos G; Varga JL; Koutselini H; Kalofoutis A
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9512-7. PubMed ID: 12867592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
    Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.
    Barabutis N; Tsellou E; Schally AV; Kouloheri S; Kalofoutis A; Kiaris H
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5575-9. PubMed ID: 17372203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
    Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV
    Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
    Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.
    Ziegler CG; Ullrich M; Schally AV; Bergmann R; Pietzsch J; Gebauer L; Gondek K; Qin N; Pacak K; Ehrhart-Bornstein M; Eisenhofer G; Bornstein SR
    Mol Cell Endocrinol; 2013 May; 371(1-2):189-94. PubMed ID: 23267837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
    Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
    Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
    Plonowski A; Schally AV; Busto R; Krupa M; Varga JL; Halmos G
    Peptides; 2002 Jun; 23(6):1127-33. PubMed ID: 12126741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI).
    Kanashiro-Takeuchi RM; Takeuchi LM; Rick FG; Dulce R; Treuer AV; Florea V; Rodrigues CO; Paulino EC; Hatzistergos KE; Selem SM; Gonzalez DR; Block NL; Schally AV; Hare JM
    Proc Natl Acad Sci U S A; 2012 Jan; 109(2):559-63. PubMed ID: 22203988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.
    Jimenez JJ; DelCanto GM; Popovics P; Perez A; Vila Granda A; Vidaurre I; Cai RZ; Rick FG; Swords RT; Schally AV
    Br J Haematol; 2018 May; 181(4):476-485. PubMed ID: 29663325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
    Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A correlation of endocrine and anticancer effects of some antagonists of GHRH.
    Kovács M; Schally AV; Hohla F; Rick FG; Pozsgai E; Szalontay L; Varga JL; Zarándi M
    Peptides; 2010 Oct; 31(10):1839-46. PubMed ID: 20633588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.
    Chu WK; Law KS; Chan SO; Yam JC; Chen LJ; Zhang H; Cheung HS; Block NL; Schally AV; Pang CP
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14396-14401. PubMed ID: 27911838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.
    Gan J; Ke X; Jiang J; Dong H; Yao Z; Lin Y; Lin W; Wu X; Yan S; Zhuang Y; Chu WK; Cai R; Zhang X; Cheung HS; Block NL; Pang CP; Schally AV; Zhang H
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14745-14750. PubMed ID: 27930339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
    Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
    Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
    Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
    Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines.
    Barabutis N; Schally AV
    Br J Cancer; 2008 Jun; 98(11):1790-6. PubMed ID: 18506184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.